Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
Livestock farming affects pulmonary function in local residents COPD patients living near livestock farms suffer more complications.
Bacteria slightly more often resistant to last resort antibiotics Antimicrobial resistance is a global problem. In the Netherlands, some bacteria that can cause infections in people are more frequently resistant to antibiotics used as a last resort.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
European Antibiotic Awareness Day: the fight against antibiotics resistance Wednesday, 18 November is European Antibiotic Awareness Day. On this day, attention throughout Europe is requested for the responsible use of antibiotics in people and animals.
More people infected with diseases transmitted by wild rodents In 2014, there were more patients in the Netherlands with diseases transmitted by wild rodents than in previous years.
CAESAR annual report 2014 The World Health Organization (WHO) published its first CAESAR annual report 2014.